{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T21:46:20Z","timestamp":1787867180575,"version":"build-2784847793"},"reference-count":115,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T00:00:00Z","timestamp":1767139200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Basic Science Research Program through the NRF","award":["RS-202400441114"],"award-info":[{"award-number":["RS-202400441114"]}]},{"name":"BK21 FOUR program through the National Research Foundation"},{"name":"Ministry of Health and Welfare (MOHW), Republic of Korea"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Triple-Negative Breast Cancer (TNBC) remains the most aggressive breast cancer subtype, characterized by profound heterogeneity and a lack of effective targeted therapies. Although cytotoxic chemotherapy is the standard of care, the rapid emergence of resistance driven by cancer stem cells (CSCs), metabolic plasticity, and the tumor microenvironment limits long-term survival. This review highlights the paradigm shift in TNBC treatment from 2021 to 2025, moving beyond broad cytotoxicity to precision medicine. We first examine the limitations of earlier targeted therapies, such as PI3K\/AKT\/mTOR inhibitors, which failed due to compensatory feedback loops and toxicity. We then discuss emerging synthetic lethality strategies targeting the G2\/M checkpoint (WEE1, ATR) and mitotic kinases (PLK1, TTK) to exploit genomic instability in TP53-mutant tumors. Furthermore, we explore how novel modalities like PROTACs and Antibody\u2013Drug Conjugates (ADCs) are unlocking the \u201cundrugged kinome,\u201d including targets like TNIK, PTK7, and PAK4, which were previously inaccessible. Finally, we propose that future success lies in combinatorial strategies integrating these next-generation kinase inhibitors with ADCs and immunotherapies to dismantle therapeutic resistance.<\/jats:p>","DOI":"10.3390\/ijms27010450","type":"journal-article","created":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T16:08:00Z","timestamp":1767197280000},"page":"450","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Overcoming Therapeutic Resistance in Triple-Negative Breast Cancer: Targeting the Undrugged Kinome"],"prefix":"10.3390","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2210-0793","authenticated-orcid":false,"given":"Chang Hoon","family":"Lee","sequence":"first","affiliation":[{"name":"BK21 FOUR Team and Integrated Research Institute for Drug Development, College of Pharmacy, Dongguk University, Goyang 10326, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6215-8266","authenticated-orcid":false,"given":"Tuan","family":"Minh Nguyen","sequence":"additional","affiliation":[{"name":"BK21 FOUR Team and Integrated Research Institute for Drug Development, College of Pharmacy, Dongguk University, Goyang 10326, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongook","family":"Lee","sequence":"additional","affiliation":[{"name":"BK21 FOUR Team and Integrated Research Institute for Drug Development, College of Pharmacy, Dongguk University, Goyang 10326, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seoung Gyu","family":"Choi","sequence":"additional","affiliation":[{"name":"BK21 FOUR Team and Integrated Research Institute for Drug Development, College of Pharmacy, Dongguk University, Goyang 10326, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phuong Ngan","family":"Nguyen","sequence":"additional","affiliation":[{"name":"BK21 FOUR Team and Integrated Research Institute for Drug Development, College of Pharmacy, Dongguk University, Goyang 10326, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jung Ho","family":"Park","sequence":"additional","affiliation":[{"name":"BK21 FOUR Team and Integrated Research Institute for Drug Development, College of Pharmacy, Dongguk University, Goyang 10326, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4257-6799","authenticated-orcid":false,"given":"Mi Kyung","family":"Park","sequence":"additional","affiliation":[{"name":"Department of Biomedical Science, Hwasung Medi-Science University, Hwaseong-si 18274, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,12,31]]},"reference":[{"key":"ref_1","first-page":"477","article-title":"Breast cancer statistics 2024","volume":"74","author":"Giaquinto","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1038\/nrc3896","article-title":"Triple-negative breast cancer in African-American women: Disparities versus biology","volume":"15","author":"Dietze","year":"2015","journal-title":"Nat. Rev. Cancer"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1093\/jnci\/djae056","article-title":"The unique risk factor profile of triple-negative breast cancer: A comprehensive meta-analysis","volume":"116","author":"Kumar","year":"2024","journal-title":"JNCI J. Natl. Cancer Inst."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2750","DOI":"10.1172\/JCI45014","article-title":"Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies","volume":"121","author":"Lehmann","year":"2011","journal-title":"J. Clin. Investig."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Cancer Genome Atlas Network (2012). Comprehensive molecular portraits of human breast tumours. Nature, 490, 70\u201384.","DOI":"10.1038\/nature11412"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1097\/PPO.0000000000000500","article-title":"Epidemiology of triple-negative breast cancer: A review","volume":"27","author":"Howard","year":"2021","journal-title":"Cancer J."},{"key":"ref_7","first-page":"101","article-title":"Prognostic Significance and Molecular Classification of Triple Negative Breast Cancer: A Systematic Review","volume":"21","author":"Dogra","year":"2025","journal-title":"Eur. J. Breast Health"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1002\/jso.28088","article-title":"Disparities in Triple Negative Breast Cancer Among Hispanic Population Living in Latin America Versus the United States","volume":"131","author":"Desai","year":"2025","journal-title":"J. Surg. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"e2537378","DOI":"10.1001\/jamanetworkopen.2025.37378","article-title":"Social Adversity and Triple-Negative Breast Cancer Incidence Among US Black Women","volume":"8","author":"Hernandez","year":"2025","journal-title":"JAMA Netw. Open"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1146\/annurev-pathol-042420-093238","article-title":"Pathogenesis of triple-negative breast cancer","volume":"17","author":"Derakhshan","year":"2022","journal-title":"Annu. Rev. Pathol. Mech. Dis."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.ccell.2019.02.001","article-title":"Genomic and transcriptomic landscape of triple-negative breast cancers: Subtypes and treatment strategies","volume":"35","author":"Jiang","year":"2019","journal-title":"Cancer Cell"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Lehmann, B.D., Jovanovi\u0107, B., Chen, X., Estrada, M.V., Johnson, K.N., Shyr, Y., Moses, H.L., Sanders, M.E., and Pietenpol, J.A. (2016). Refinement of triple-negative breast cancer molecular subtypes: Implications for neoadjuvant chemotherapy selection. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0157368"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1200\/JCO.2016.71.3495","article-title":"Enzalutamide for the treatment of androgen receptor\u2013expressing triple-negative breast cancer","volume":"36","author":"Traina","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1158\/1078-0432.CCR-14-0432","article-title":"Comprehensive genomic analysis identifies novel subtypes and targets of triple-negative breast cancer","volume":"21","author":"Burstein","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1038\/nrclinonc.2016.66","article-title":"Triple-negative breast cancer: Challenges and opportunities of a heterogeneous disease","volume":"13","author":"Bianchini","year":"2016","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1200\/JCO.2011.38.8595","article-title":"Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes","volume":"30","author":"Untch","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/S0140-6736(13)62422-8","article-title":"Pathological complete response and long-term clinical benefit in breast cancer: The CTNeoBC pooled analysis","volume":"384","author":"Cortazar","year":"2014","journal-title":"Lancet"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1200\/JCO.2007.14.4147","article-title":"Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer","volume":"26","author":"Liedtke","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1200\/JCO.2015.63.1010","article-title":"Long-term prognostic risk after neoadjuvant chemotherapy associated with residual cancer burden and breast cancer subtype","volume":"35","author":"Symmans","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"3983","DOI":"10.1073\/pnas.0530291100","article-title":"Prospective identification of tumorigenic breast cancer cells","volume":"100","author":"Wicha","year":"2003","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"13820","DOI":"10.1073\/pnas.0905718106","article-title":"Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features","volume":"106","author":"Creighton","year":"2009","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1016\/S0140-6736(23)00285-4","article-title":"Anthracycline-containing and taxane-containing chemotherapy for early-stage operable breast cancer: A patient-level meta-analysis of 100,000 women from 86 randomised trials","volume":"401","author":"Braybrooke","year":"2023","journal-title":"Lancet"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/S1470-2045(19)30689-8","article-title":"Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): Updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"21","author":"Schmid","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1056\/NEJMoa2202809","article-title":"Pembrolizumab plus chemotherapy in advanced triple-negative breast cancer","volume":"387","author":"Cortes","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1016\/S0140-6736(20)32531-9","article-title":"Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): A randomised, placebo-controlled, double-blind, phase 3 clinical trial","volume":"396","author":"Cortes","year":"2020","journal-title":"Lancet"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"5628","DOI":"10.1002\/jcp.27419","article-title":"Antibody\u2013drug conjugates (ADCs) for cancer therapy: Strategies, challenges, and successes","volume":"234","author":"Lotfinia","year":"2019","journal-title":"J. Cell. Physiol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1038\/d41573-021-00054-2","article-title":"The oncology market for antibody-drug conjugates","volume":"20","author":"Nawaz","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"5441","DOI":"10.1158\/1078-0432.CCR-19-0272","article-title":"Antibody\u2013drug conjugates: Future directions in clinical and translational strategies to improve the therapeutic index","volume":"25","author":"Coats","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1158\/1541-7786.MCR-19-0582","article-title":"Antibody\u2013drug conjugates: A comprehensive review","volume":"18","author":"Khongorzul","year":"2020","journal-title":"Mol. Cancer Res."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"22496","DOI":"10.18632\/oncotarget.4318","article-title":"Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC)","volume":"6","author":"Goldenberg","year":"2015","journal-title":"Oncotarget"},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Yao, L., Chen, J., and Ma, W. (2023). Decoding TROP2 in breast cancer: Significance, clinical implications, and therapeutic advancements. Front. Oncol., 13.","DOI":"10.3389\/fonc.2023.1292211"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"3157","DOI":"10.1158\/1078-0432.CCR-10-2939","article-title":"Humanized anti-Trop-2 IgG-SN-38 conjugate for effective treatment of diverse epithelial cancers: Preclinical studies in human cancer xenograft models and monkeys","volume":"17","author":"Cardillo","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"3843","DOI":"10.1002\/cncr.30789","article-title":"Sacituzumab govitecan (IMMU-132), an anti-Trop-2-SN-38 antibody-drug conjugate for the treatment of diverse epithelial cancers: Safety and pharmacokinetics","volume":"123","author":"Ocean","year":"2019","journal-title":"Cancer"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"5131","DOI":"10.1158\/1078-0432.CCR-15-0670","article-title":"Enhanced delivery of SN-38 to human tumor xenografts with an anti-trop-2\u2013SN-38 antibody conjugate (sacituzumab govitecan)","volume":"21","author":"Sharkey","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1158\/2159-8290.CD-21-0702","article-title":"Parallel genomic alterations of antigen and payload targets mediate polyclonal acquired clinical resistance to sacituzumab govitecan in triple-negative breast cancer","volume":"11","author":"Coates","year":"2021","journal-title":"Cancer Discov."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1056\/NEJMoa2028485","article-title":"Sacituzumab govitecan in metastatic triple-negative breast cancer","volume":"384","author":"Bardia","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1016\/j.annonc.2021.06.002","article-title":"Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer","volume":"32","author":"Bardia","year":"2021","journal-title":"Ann. Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1038\/s41523-022-00467-1","article-title":"Safety analyses from the phase 3 ASCENT trial of sacituzumab govitecan in metastatic triple-negative breast cancer","volume":"8","author":"Rugo","year":"2022","journal-title":"npj Breast Cancer"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.ejca.2022.10.003","article-title":"Health-related quality of life in the phase III ASCENT trial of sacituzumab govitecan versus standard chemotherapy in metastatic triple-negative breast cancer","volume":"178","author":"Loibl","year":"2023","journal-title":"Eur. J. Cancer"},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Joubert, N., Beck, A., Dumontet, C., and Denevault-Sabourin, C. (2020). Antibody\u2013drug conjugates: The last decade. Pharmaceuticals, 13.","DOI":"10.3390\/ph13090245"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1158\/1535-7163.MCT-16-0219","article-title":"Combining ABCG2 inhibitors with IMMU-132, an anti\u2013trop-2 antibody conjugate of SN-38, overcomes resistance to SN-38 in breast and gastric cancers","volume":"15","author":"Chang","year":"2016","journal-title":"Mol. Cancer Ther."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1200\/JCO.24.00920","article-title":"Datopotamab deruxtecan versus chemotherapy in previously treated inoperable\/metastatic hormone receptor\u2013positive human epidermal growth factor receptor 2\u2013negative breast cancer: Primary results from TROPION-Breast01","volume":"43","author":"Bardia","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2203690","article-title":"Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer","volume":"387","author":"Modi","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.1158\/2159-8290.CD-22-0703","article-title":"Navigating the HER2-low paradigm in breast oncology: New standards, future horizons","volume":"12","author":"Tarantino","year":"2022","journal-title":"Cancer Discov."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1016\/j.annonc.2020.07.014","article-title":"Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: A report from the ESMO Precision Medicine Working Group","volume":"31","author":"Mosele","year":"2020","journal-title":"Ann. Oncol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"5550","DOI":"10.1200\/JCO.23.00882","article-title":"Patritumab deruxtecan (HER3-DXd), a human epidermal growth factor receptor 3\u2013directed antibody-drug conjugate, in patients with previously treated human epidermal growth factor receptor 3\u2013expressing metastatic breast cancer: A multicenter, phase I\/II trial","volume":"41","author":"Krop","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"4429","DOI":"10.1158\/1078-0432.CCR-06-3045","article-title":"Triple-negative breast cancer: Clinical features and patterns of recurrence","volume":"13","author":"Dent","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.stem.2007.08.014","article-title":"ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome","volume":"1","author":"Ginestier","year":"2007","journal-title":"Cell Stem Cell"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"3931","DOI":"10.1073\/pnas.1213394110","article-title":"DNA damage in stem cells activates p21, inhibits p53, and induces symmetric self-renewing divisions","volume":"110","author":"Insinga","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1172\/JCI65416","article-title":"TGF-\u03b2 inhibition enhances chemotherapy action against triple-negative breast cancer","volume":"123","author":"Bhola","year":"2013","journal-title":"J. Clin. Investig."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"2784","DOI":"10.1073\/pnas.1018866109","article-title":"Antiangiogenic agents increase breast cancer stem cells via the generation of tumor hypoxia","volume":"109","author":"Conley","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Nedeljkovi\u0107, M., and Damjanovi\u0107, A. (2019). Mechanisms of chemotherapy resistance in triple-negative breast cancer\u2014How we can rise to the challenge. Cells, 8.","DOI":"10.3390\/cells8090957"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/s41568-018-0005-8","article-title":"Revisiting the role of ABC transporters in multidrug-resistant cancer","volume":"18","author":"Robey","year":"2018","journal-title":"Nat. Rev. Cancer"},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Chen, W., Qin, Y., Wang, D., Zhou, L., Liu, Y., Chen, S., Yin, L., Xiao, Y., Yao, X.-H., and Yang, X. (2018). CCL20 triggered by chemotherapy hinders the therapeutic efficacy of breast cancer. PLoS Biol., 16.","DOI":"10.1371\/journal.pbio.2005869"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.drup.2015.02.002","article-title":"Overcoming the blood\u2013brain tumor barrier for effective glioblastoma treatment","volume":"19","author":"Wesseling","year":"2015","journal-title":"Drug Resist. Updates"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1586\/14737140.7.4.447","article-title":"Tariquidar (XR9576): A P-glycoprotein drug efflux pump inhibitor","volume":"7","author":"Fox","year":"2007","journal-title":"Expert Rev. Anticancer. Ther."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"5572","DOI":"10.1158\/0008-5472.CAN-20-3242","article-title":"Oxidative phosphorylation is a metabolic vulnerability in chemotherapy-resistant triple-negative breast cancer","volume":"81","author":"Evans","year":"2021","journal-title":"Cancer Res."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"44","DOI":"10.20892\/j.issn.2095-3941.2019.0210","article-title":"Metabolic reprogramming in triple-negative breast cancer","volume":"17","author":"Wang","year":"2020","journal-title":"Cancer Biol. Med."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1038\/nature10598","article-title":"Nuclear PKM2 regulates \u03b2-catenin transactivation upon EGFR activation","volume":"480","author":"Yang","year":"2011","journal-title":"Nature"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1038\/nrc3483","article-title":"Cancer metabolism: Fatty acid oxidation in the limelight","volume":"13","author":"Carracedo","year":"2013","journal-title":"Nat. Rev. Cancer"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1038\/nm.4055","article-title":"Inhibition of fatty acid oxidation as a therapy for MYC-overexpressing triple-negative breast cancer","volume":"22","author":"Camarda","year":"2016","journal-title":"Nat. Med."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.ccr.2013.08.020","article-title":"Glutamine sensitivity analysis identifies the xCT antiporter as a common triple-negative breast tumor therapeutic target","volume":"24","author":"Timmerman","year":"2013","journal-title":"Cancer Cell"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.cmet.2016.08.011","article-title":"LDHA-associated lactic acid production blunts tumor immunosurveillance by T and NK cells","volume":"24","author":"Brand","year":"2016","journal-title":"Cell Metab."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1038\/s41586-018-0392-8","article-title":"Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response","volume":"560","author":"Chen","year":"2018","journal-title":"Nature"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1039\/c5ib00040h","article-title":"Human breast cancer invasion and aggression correlates with ECM stiffening and immune cell infiltration","volume":"7","author":"Acerbi","year":"2015","journal-title":"Integr. Biol."},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Provenzano, P.P., Eliceiri, K.W., Campbell, J.M., Inman, D.R., White, J.G., and Keely, P.J. (2006). Collagen reorganization at the tumor-stromal interface facilitates local invasion. BMC Med., 4.","DOI":"10.1186\/1741-7015-4-38"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1038\/ncb3157","article-title":"Matrix stiffness drives epithelial\u2013mesenchymal transition and tumour metastasis through a TWIST1\u2013G3BP2 mechanotransduction pathway","volume":"17","author":"Wei","year":"2015","journal-title":"Nat. Cell Biol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"3664","DOI":"10.1172\/JCI67230","article-title":"HIF-1 mediates metabolic responses to intratumoral hypoxia and oncogenic mutations","volume":"123","author":"Semenza","year":"2013","journal-title":"J. Clin. Investig."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1001\/jamaoncol.2018.4224","article-title":"Long-term clinical outcomes and biomarker analyses of atezolizumab therapy for patients with metastatic triple-negative breast cancer: A phase 1 study","volume":"5","author":"Emens","year":"2019","journal-title":"JAMA Oncol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.2217\/fon.13.92","article-title":"Role of hypoxia-inducible factors in breast cancer metastasis","volume":"9","author":"Gilkes","year":"2013","journal-title":"Future Oncol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1038\/s41590-020-00834-9","article-title":"Mitochondrial stress induced by continuous stimulation under hypoxia rapidly drives T cell exhaustion","volume":"22","author":"Scharping","year":"2021","journal-title":"Nat. Immunol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"5137","DOI":"10.1172\/JCI96268","article-title":"Targeted hypoxia reduction restores T cell infiltration and sensitizes prostate cancer to immunotherapy","volume":"128","author":"Jayaprakash","year":"2018","journal-title":"J. Clin. Investig."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1038\/s41591-019-0382-x","article-title":"Genomic correlates of response to immune checkpoint blockade","volume":"25","author":"Keenan","year":"2019","journal-title":"Nat. Med."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1038\/s41467-020-16199-4","article-title":"Targeting lysyl oxidase (LOX) overcomes chemotherapy resistance in triple negative breast cancer","volume":"11","author":"Saatci","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.cell.2009.06.034","article-title":"Identification of selective inhibitors of cancer stem cells by high-throughput screening","volume":"138","author":"Gupta","year":"2019","journal-title":"Cell"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1038\/s41591-018-0052-4","article-title":"An inhibitor of oxidative phosphorylation exploits cancer vulnerability","volume":"24","author":"Molina","year":"2018","journal-title":"Nat. Med."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1152\/physrev.00038.2010","article-title":"Normalization of the vasculature for treatment of cancer and other diseases","volume":"91","author":"Goel","year":"2011","journal-title":"Physiol. Rev."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1007\/s10549-018-4697-y","article-title":"Targeting the PI3K\/AKT\/mTOR pathway in triple-negative breast cancer: A review","volume":"169","author":"Costa","year":"2018","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1038\/s41586-018-0343-4","article-title":"Suppression of insulin feedback enhances the efficacy of PI3K inhibitors","volume":"560","author":"Hopkins","year":"2018","journal-title":"Nature"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.1158\/1078-0432.CCR-09-2229","article-title":"Crosstalk between insulin\/insulin-like growth factor-1 receptors and G protein-coupled receptor signaling systems: A novel target for the antidiabetic drug metformin in pancreatic cancer","volume":"16","author":"Rozengurt","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1200\/JCO.19.00368","article-title":"Capivasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer: The PAKT trial","volume":"38","author":"Schmid","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"4329","DOI":"10.1158\/1078-0432.CCR-24-0465","article-title":"Ipatasertib plus paclitaxel for patients with PIK3CA\/AKT1\/PTEN-altered locally advanced unresectable or metastatic triple-negative breast cancer in the IPATunity130 phase III trial","volume":"30","author":"Dent","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.ccr.2010.10.031","article-title":"AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity","volume":"19","author":"Chandarlapaty","year":"2011","journal-title":"Cancer Cell"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"5462","DOI":"10.7150\/jca.97775","article-title":"Autophagy modulation in therapeutic strategy of breast cancer drug resistance","volume":"15","author":"Wang","year":"2024","journal-title":"J. Cancer"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/nature16508","article-title":"Response and resistance to BET bromodomain inhibitors in triple-negative breast cancer","volume":"529","author":"Shu","year":"2016","journal-title":"Nature"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1200\/JCO.22.00830","article-title":"Multicenter phase II trial of the WEE1 inhibitor adavosertib in refractory solid tumors harboring CCNE1 amplification","volume":"41","author":"Fu","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"4751","DOI":"10.1158\/1078-0432.CCR-23-1696","article-title":"Olaparib and ceralasertib (AZD6738) in patients with triple-negative advanced breast cancer: Results from cohort E of the plasmaMATCH trial (CRUK\/15\/010)","volume":"29","author":"Ring","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1038\/s41586-022-04638-9","article-title":"CCNE1 amplification is synthetic lethal with PKMYT1 kinase inhibition","volume":"604","author":"Gallo","year":"2022","journal-title":"Nature"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1038\/s41591-023-02399-0","article-title":"Camonsertib in DNA damage response-deficient advanced solid tumors: Phase 1 trial results","volume":"29","author":"Yap","year":"2023","journal-title":"Nat. Med."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.pharmthera.2019.05.009","article-title":"Schlafen 11 (SLFN11), a restriction factor for replicative stress induced by DNA-targeting anti-cancer therapies","volume":"201","author":"Murai","year":"2019","journal-title":"Pharmacol. Ther."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"3701","DOI":"10.2217\/fon-2022-0773","article-title":"Trilaciclib prior to gemcitabine plus carboplatin for metastatic triple-negative breast cancer: Phase III PRESERVE 2","volume":"18","author":"Goel","year":"2022","journal-title":"Future Oncol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"PS2-05","DOI":"10.1158\/1557-3265.SABCS24-PS2-05","article-title":"Abstract PS2-05: PRESERVE 2: A randomized, phase 3, double-blind trial of trilaciclib or placebo in patients (pts) receiving first-line gemcitabine\/carboplatin (GCb) for locally advanced or metastatic triple-negative breast cancer (mTNBC)","volume":"31","author":"Goel","year":"2025","journal-title":"Clin. Cancer Res."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1038\/nrd3184","article-title":"Multifaceted polo-like kinases: Drug targets and antitargets for cancer therapy","volume":"9","author":"Strebhardt","year":"2010","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1158\/0008-5472.CAN-12-2633","article-title":"Polo-like kinase 1: A potential therapeutic option in combination with conventional chemotherapy for the management of patients with triple-negative breast cancer","volume":"73","author":"Maire","year":"2013","journal-title":"Cancer Res."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1002\/med.21392","article-title":"Spotlight on volasertib: Preclinical and clinical evaluation of a promising Plk1 inhibitor","volume":"36","author":"Lardon","year":"2016","journal-title":"Med. Res. Rev."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1200\/JCO.2025.43.16_suppl.1100","article-title":"A phase 1b study of Plk1 inhibitor onvansertib in combination with paclitaxel in metastatic triple-negative breast cancer (mTNBC) patients","volume":"43","author":"Giordano","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1158\/1535-7163.MCT-11-0765","article-title":"NMS-P937, an orally available, specific small-molecule polo-like kinase 1 inhibitor with antitumor activity in solid and hematologic malignancies","volume":"11","author":"Valsasina","year":"2012","journal-title":"Mol. Cancer Ther."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"101","DOI":"10.3892\/or.2024.8760","article-title":"Energy-stress-mediated activation of AMPK sensitizes MPS1 kinase inhibition in triple-negative breast cancer","volume":"52","author":"Lim","year":"2024","journal-title":"Oncol. Rep."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"e214103","DOI":"10.1001\/jamanetworkopen.2021.4103","article-title":"Efficacy and safety of weekly paclitaxel with or without oral alisertib in patients with metastatic breast cancer: A randomized clinical trial","volume":"4","author":"McIntyre","year":"2021","journal-title":"JAMA Netw. Open"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1007\/s12672-025-03825-0","article-title":"Aurora Kinase A inhibitor alisertib failed to exert its efficacy on TNBC cells due to consequential enrichment of polyploid giant cancer cells (PGCCs)","volume":"16","author":"Thakur","year":"2025","journal-title":"Discov. Oncol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1002\/pros.23877","article-title":"Polyploid giant cancer cells: Unrecognized actuators of tumorigenesis, metastasis, and resistance","volume":"79","author":"Amend","year":"2019","journal-title":"Prostate"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"12586","DOI":"10.1038\/ncomms12586","article-title":"TNIK inhibition abrogates colorectal cancer stemness","volume":"7","author":"Masuda","year":"2016","journal-title":"Nat. Commun."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"e310","DOI":"10.1038\/oncsis.2017.14","article-title":"Wnt signaling in triple-negative breast cancer","volume":"6","author":"Pohl","year":"2017","journal-title":"Oncogenesis"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/nature14404","article-title":"Melanoma-intrinsic \u03b2-catenin signalling prevents anti-tumour immunity","volume":"523","author":"Spranger","year":"2015","journal-title":"Nature"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1038\/s41388-024-03060-x","article-title":"Recent insights into the therapeutic strategies targeting the pseudokinase PTK7 in cancer","volume":"43","author":"Dessaux","year":"2024","journal-title":"Oncogene"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"eaag2611","DOI":"10.1126\/scitranslmed.aag2611","article-title":"A PTK7-targeted antibody-drug conjugate reduces tumor-initiating cells and induces sustained tumor regressions","volume":"9","author":"Damelin","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"215813","DOI":"10.1016\/j.canlet.2022.215813","article-title":"PAK4 in cancer development: Emerging player and therapeutic opportunities","volume":"545","author":"Yuan","year":"2022","journal-title":"Cancer Lett."},{"key":"ref_108","first-page":"46","article-title":"PAK4 inhibition improves PD-1 blockade immunotherapy","volume":"1","author":"Torrejon","year":"2020","journal-title":"Nat. Cancer"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/s41573-021-00371-6","article-title":"PROTAC targeted protein degraders: The past is prologue","volume":"21","author":"Langley","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1038\/s41586-024-08031-6","article-title":"AKT and EZH2 inhibitors kill TNBCs by hijacking mechanisms of involution","volume":"635","author":"Schade","year":"2024","journal-title":"Nature"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1080\/17435889.2025.2550233","article-title":"Strategies to enhance the effects of nanotechnology-mediated photodynamic therapy","volume":"20","author":"Mo","year":"2025","journal-title":"Nanomedicine"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1038\/nrc1977","article-title":"Topoisomerase I inhibitors: Camptothecins and beyond","volume":"6","author":"Pommier","year":"2006","journal-title":"Nat. Rev. Cancer"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"915","DOI":"10.20892\/j.issn.2095-3941.2023.0260","article-title":"Advances in ATM, ATR, WEE1, and CHK1\/2 inhibitors in the treatment of PARP inhibitor-resistant ovarian cancer","volume":"20","author":"Tang","year":"2024","journal-title":"Cancer Biol. Med."},{"key":"ref_114","first-page":"1023","article-title":"BEGONIA: Phase 1b\/2 study of durvalumab (D) combinations in locally advanced\/metastatic triple-negative breast cancer (TNBC)\u2014Initial results from arm 1, d+ paclitaxel (P), and arm 6, d+ trastuzumab deruxtecan (T-DXd)","volume":"39","author":"Schmid","year":"2021","journal-title":"Wolters Kluwer Health"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/s41571-021-00470-8","article-title":"Unlocking the potential of antibody\u2013drug conjugates for cancer therapy","volume":"18","author":"Drago","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/1\/450\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T12:41:13Z","timestamp":1767616873000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/1\/450"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,31]]},"references-count":115,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1]]}},"alternative-id":["ijms27010450"],"URL":"https:\/\/doi.org\/10.3390\/ijms27010450","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,31]]}}}